Competition & Peer Data API & CSV Delivery

Oxford Immunotec Global Plc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Oxford Immunotec Global Plc (OXFD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2020
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-8.40 %
Q3 2020
Net Margin
-0.77 %
Q3 2020

Key Findings: Oxford Immunotec Global Plc vs Its Competitors

  • TTM: Trailing 12-month revenue of 57M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+35.7% annualized vs trailing 12 months).
  • Peer revenue share: Oxford Immunotec Global Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

OXFD Sales vs. its Competitors, Q3 2020

Oxford Immunotec Global Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/OXFD/competitors
https://api.csimarket.com/api/v1/companies/OXFD/relationships
https://api.csimarket.com/api/v1/companies/OXFD/similar
Programmatic access for models, analytics, and integration workflows.

For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs -8.4% for Oxford Immunotec Global Plc. Oxford Immunotec Global Plc's share of combined industry revenue moved from 0.63% to 0.57%, a loss of 0.07 percentage points.

Oxford Immunotec Global Plc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Oxford Immunotec Global Plc No No No No
Similar Growth & Profitability (8) 0.00 % (0 of 8) 25.00 % (2 of 8) 25.00 % (2 of 8) 28.60 % (2 of 7)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q3 2020

100%market share
  • Oxford Immunotec Global Plc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Oxford Immunotec Global Plc and its 0 tracked competitors.

See Oxford Immunotec Global Plc's full market share breakdown »

OXFD Stock Performance relative to its Competitors

OXFD Competitors (weighted) Percent change over the selected range

OXFD Stock Performance relative to Similar Growth & Profitability Competitors

OXFD Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range